Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ARIA [NASD]
Ariad Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own1.30% Shs Outstand187.02M Perf Week-3.35%
Market Cap1.08B Forward P/E- EPS next Y-0.71 Insider Trans83.18% Shs Float181.30M Perf Month-4.79%
Income-247.20M PEG- EPS next Q-0.30 Inst Own66.60% Short Float27.83% Perf Quarter-13.36%
Sales49.00M P/S22.02 EPS this Y-11.20% Inst Trans11.67% Short Ratio6.99 Perf Half Y-26.40%
Book/sh0.66 P/B8.74 EPS next Y38.30% ROA-61.20% Target Price8.72 Perf Year-73.15%
Cash/sh1.66 P/C3.48 EPS next 5Y41.40% ROE-139.80% 52W Range2.15 - 21.55 Perf YTD-15.40%
Dividend- P/FCF- EPS past 5Y-7.90% ROI-93.20% 52W High-73.23% Beta1.49
Dividend %- Quick Ratio5.10 Sales past 5Y45.10% Gross Margin73.90% 52W Low168.37% ATR0.23
Employees307 Current Ratio5.10 Sales Q/Q-13.60% Oper. Margin- RSI (14)43.78 Volatility3.84% 3.97%
OptionableYes Debt/Eq2.42 EPS Q/Q18.90% Profit Margin- Rel Volume1.33 Prev Close5.76
ShortableYes LT Debt/Eq2.42 EarningsAug 06 BMO Payout- Avg Volume7.21M Price5.77
Recom2.60 SMA20-4.38% SMA50-0.96% SMA200-14.04% Volume9,622,810 Change0.17%
25-Mar-14Resumed HC Wainwright Buy $14
26-Feb-14Upgrade Maxim Group Hold → Buy $11
26-Feb-14Downgrade Chardan Capital Markets Buy → Neutral
24-Jan-14Upgrade BMO Capital Markets Market Perform → Outperform $8 → $14
06-Jan-14Reiterated UBS Neutral $2.50 → $7.50
23-Dec-13Upgrade Chardan Capital Markets Neutral → Buy $9
20-Dec-13Reiterated BMO Capital Markets Market Perform $4 → $8
10-Dec-13Upgrade Stifel Hold → Buy $7
21-Oct-13Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $4
14-Oct-13Downgrade Argus Hold → Sell
10-Oct-13Reiterated Oppenheimer Outperform $24 → $7
10-Oct-13Downgrade Summer Street Research Buy → Neutral
10-Oct-13Downgrade Chardan Capital Markets Buy → Neutral
10-Oct-13Downgrade Barclays Overweight → Underweight $25 → $4
09-Oct-13Downgrade Maxim Group Buy → Hold $24
30-Sep-13Upgrade Oppenheimer Perform → Outperform $23 → $24
30-Sep-13Reiterated Maxim Group Buy $26 → $24
04-Sep-13Initiated Chardan Capital Markets Buy $28
26-Feb-13Reiterated Barclays Overweight $30 → $29
03-Jan-13Reiterated UBS Buy $29 → $26
19-Sep-14 12:05PM  Ariad Director Resignation May Mean CEO Berger One Step Closer to Exit at TheStreet
18-Sep-14 04:06PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
16-Sep-14 12:31PM  INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER Thomson Reuters ONE
05-Sep-14 08:55AM  Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte at TheStreet
04-Sep-14 06:00AM  'Mad Money' Lightning Round: Yahoo! Is One of the Best Buys Around at TheStreet
27-Aug-14 05:03PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
26-Aug-14 12:36PM  Why Ariad Pharmaceuticals (ARIA) Stock Is Up Today at TheStreet
21-Aug-14 02:11PM  5 Stocks Insiders Love Right Now at TheStreet
15-Aug-14 01:04PM  ARIAD PHARMACEUTICALS INC Financials EDGAR Online Financials
11-Aug-14 12:10PM  ARIAD Falls on Wider-than-Expected Loss, Revenues Miss Zacks
08-Aug-14 04:30PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
06-Aug-14 01:07PM  Why Ariad Pharmaceuticals (ARIA) Stock Is Down Today TheStreet
08:30AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
08:19AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:40AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure EDGAR Online
07:35AM  ARIAD Reports Second Quarter 2014 Financial Results and Development Progress Business Wire
07:34AM  ARIAD Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today CCBN
07:07AM  Q2 2014 ARIAD Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
05-Aug-14 03:45PM  Will GW Pharmaceuticals (GWPH) Miss this Earnings Season? Zacks
07:35AM  ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel Business Wire
06:41AM  Should You Sell Ariad Pharmaceuticals (ARIA) Before Earnings? Zacks
04-Aug-14 03:01PM  17 stocks traders are shorting ahead of earnings at CNBC
01-Aug-14 08:43AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics Zacks
29-Jul-14 02:35PM  Storm The Castle: ARIAD Pharmaceuticals (ARIA) at TheStreet +9.98%
25-Jul-14 09:49AM  ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today at TheStreet
24-Jul-14 07:31AM  Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Gains 15.3% Zacks +5.10%
05:00AM  'Fast Money' Recap: Facebook and Analysts' Expectations at TheStreet
16-Jul-14 07:35AM  ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results Business Wire
15-Jul-14 05:02PM  Ariad Stock's Biggest Risk Is Its Only Hope at Motley Fool -5.11%
14-Jul-14 07:35AM  ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe Business Wire
08-Jul-14 10:39AM  ARIAD Pharmaceuticals (ARIA) Is Water-Logged And Getting Wetter Today at TheStreet
07-Jul-14 05:10PM  UCB, Dermira Sign Cimzia Dermatology Deal Zacks
03:30PM  OncoGenex's Apatorsen in Phase II for Lung Cancer Zacks
07:42AM  Why A Short Covering Rally Might Come for Ariad Pharmaceuticals (ARIA) Stock Zacks
03-Jul-14 07:03AM  Zogenix, Inc. (ZGNX) Soars: Stock Adds 18.6% in Session Zacks
02-Jul-14 04:55PM  Amgen Gets Breakthrough Therapy Status for Leukemia Drug Zacks
06:45AM  Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% Zacks
06:41AM  Salix Pharmaceuticals (SLXP) Soars: Stock Adds 11.4% in Session Zacks
01-Jul-14 08:10AM  IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% Zacks
06:54AM  Auxilium Pharmaceuticals (AUXL) Crumbles: Stock Falls by 5.6% Zacks
30-Jun-14 10:50AM  UCB's Vimpat Positive for Partial-Onset Seizures Zacks
27-Jun-14 06:32AM  QLT Inc. (QLTI) in Focus: Stock Surges 14.63% Zacks
06:32AM  QLT Inc. (QLTI) in Focus: Stock Surges 14.63%
26-Jun-14 06:02AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V EDGAR Online
06:02AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V
24-Jun-14 04:51PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex EDGAR Online
04:51PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
06:59AM  Ohr Pharmaceutical (OHRP) Soars: Stock Adds 16.9% in Session
06:56AM  Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% Zacks
06:56AM  Weakness Seen in Alcobra (ADHD): Stock Falls 6.7%
23-Jun-14 07:35AM  ARIAD Announces Three Key Appointments to Its Global Management Team Business Wire
07:35AM  ARIAD Announces Three Key Appointments to Its Global Management Team
06:40AM  Weakness Seen in Cerulean Pharma (CERU): Stock Slumps 20.1%
22-Jun-14 05:31PM  FDA Drops the Hammer on Twitter at Motley Fool
05:31PM  FDA Drops the Hammer on Twitter
20-Jun-14 04:20PM  Tetraphase Progresses with Eravacycline Late-Stage Study Zacks
01:49AM  Aerie Pharmaceuticals (AERI) in Focus: Stock Moves 6.8% Higher Zacks
01:49AM  Aerie Pharmaceuticals (AERI) in Focus: Stock Moves 6.8% Higher
19-Jun-14 05:10PM  BioLineRx to Commence BL-8040 Study Zacks
05:10PM  BioLineRx to Commence BL-8040 Study
07:58AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
07:58AM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:19AM  Endocyte (ECYT) in Focus: Stock Tanks 14% Zacks
07:19AM  Endocyte (ECYT) in Focus: Stock Tanks 14%
07:00AM  Receptos (RCPT) in Focus: Stock Up 6.5% Zacks
06:59AM  Flexion Therapeutics, Inc. (FLXN) Soars: Stock Adds 15.7% in Session Zacks
06:59AM  Flexion Therapeutics, Inc. (FLXN) Soars: Stock Adds 15.7% in Session
18-Jun-14 11:10AM  Merck Backs Out of Endocyte Vintafolide Deal Zacks
11:10AM  Merck Backs Out of Endocyte Vintafolide Deal
17-Jun-14 04:54PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ EDGAR Online
04:54PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
16-Jun-14 02:27PM  3 Biotech Stocks Backed By Big Money Benzinga
08:47AM  Five Biotech Stocks With Big Potential And Billionaire Believers at Forbes
08:47AM  Five Biotech Stocks With Big Potential And Billionaire Believers
06:46AM  Nektar Therapeutics (NKTR) in Focus: Stock Rises 10.77% Zacks
06:46AM  Nektar Therapeutics (NKTR) in Focus: Stock Rises 10.77%
06:46AM  WuXi PharmaTech (WX) in Focus: Stock Falls 6.4% Zacks
13-Jun-14 09:31AM  Why A Short Covering Rally Might Come for Ariad (ARIA) Stock Zacks
08:24AM  Onconova Therapeutics (ONTX) in Focus: Stock Up 14.0% Zacks
12-Jun-14 06:29PM  Most active Nasdaq-traded stocks AP -8.69%
01:19PM  Most active Nasdaq-traded stocks AP
09:23AM  Will This Price Target Decrease Hurt Ariad Pharmaceuticals (ARIA) Stock Today? at TheStreet
09:15AM  ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019 Business Wire
08:27AM  The Zacks Analyst Blog Highlights: Clovis, Biogen, Halozyme, Ariad and Chart Industries Zacks
06:48AM  Auxilium Pharmaceuticals (AUXL) in Focus: Stock Tumbles 7.8% Zacks
02:25AM  Alcobra Ltd. (ADHD) Jumps: Stock Rises 8.7% Zacks
11-Jun-14 04:54PM  Why Ariad Pharmaceuticals (ARIA) Stock Is Down in After-Hours Trading Today at TheStreet
04:01PM  ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019 Business Wire
11:16AM  Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted Zacks
08:06AM  KaloBios (KBIO) Worth Watching: Stock Jumps 12.7% Zacks
07:35AM  ARIAD Announces Webcast of Its Annual Shareholders Meeting Business Wire
06:46AM  Strength Seen in Receptos, Inc. (RCPT) as Stock Shoots up 36.78% Zacks
09-Jun-14 03:52PM  Why Investors Are Wrong about Ariad at Motley Fool
06:45AM  Aerie Pharmaceuticals, Inc. (AERI) in Focus: Stock Rises 5.71% Zacks
06:42AM  Hyperion (HPTX) in Focus: Stock Tumbles 9.5% Zacks
05-Jun-14 04:06PM  ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
11:28AM  ASCO: Cancer Drug Showdown at Motley Fool
10:12AM  Insider Trading Alert - ENTA, REX And ARIA Traded By Insiders at TheStreet
03-Jun-14 11:21AM  ARIAD Pharmaceuticals (ARIA) Is Today's Perilous Reversal Stock at TheStreet
06:44AM  Ariad Pharmaceuticals (ARIA) Catches Eye: Stock Up 7.43% Zacks
ARIAD Pharmaceuticals, Inc., an oncology company, is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. The company is also developing Iclusig for other blood cancers and solid tumors, such as gastrointestinal stromal tumors, acute myeloid leukemia, and certain forms of non-small cell lung cancer; and various investigator-sponsored trials in indications, including first line and second line CML, acute myeloid leukemia, non-small cell lung cancer, and medullary thyroid cancer. In addition, its product pipeline consists of AP26113, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schlesinger Sarah J.DirectorSep 10Buy5.751,3007,4755,200Sep 11 04:38 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerSep 09Option Exercise5.237,82540,925147,983Sep 11 04:41 PM
BERGER HARVEY J M DChairman & CEOSep 09Option Exercise5.23150,000784,5001,294,277Sep 11 04:39 PM
Schlesinger Sarah J.DirectorSep 09Buy5.931,3007,7093,900Sep 11 04:38 PM
BERGER HARVEY J M DChairman & CEOSep 03Buy6.3112,50078,8591,739,286Sep 11 04:39 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 02Option Exercise1.3026,25034,125179,705Sep 04 04:21 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 02Option Exercise5.2350,000261,500305,960Sep 04 04:24 PM
BERGER HARVEY J M DChairman & CEOSep 02Buy6.2212,50077,7781,726,786Sep 11 04:39 PM
Cantor Maria ESVP, Corporate Affairs and HRSep 02Sale6.212,69616,75388,678Sep 04 04:22 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualitySep 02Sale6.2256,650352,227123,055Sep 04 04:21 PM
FITZGERALD EDWARD MExecutive VP, CFOSep 02Sale6.2250,000310,835280,960Sep 04 04:24 PM
DENNER ALEXANDER JDirectorAug 15Buy5.83850,0004,955,5007,798,665Aug 19 06:04 PM
Schlesinger Sarah J.DirectorAug 13Buy5.711,3007,4232,600Sep 11 04:38 PM
Schlesinger Sarah J.DirectorAug 12Buy5.521,3007,1761,300Sep 11 04:38 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerJul 15Option Exercise0.008,0000238,642Jul 17 05:04 PM
CLACKSON TIMOTHY PPresident, R&D, CSOJul 15Option Exercise0.0014,0000418,129Jul 17 05:02 PM
Haluska FrankSVP, Clinical R&D, CMOJul 15Option Exercise0.008,000097,907Jul 17 05:01 PM
FITZGERALD EDWARD MExecutive VP, CFOJul 15Option Exercise0.0014,0000285,524Jul 17 05:00 PM
Duvall Martin JEVP, CCOJul 15Option Exercise0.002,800036,363Jul 17 04:58 PM
BERGER HARVEY J M DChairman & CEOJul 15Option Exercise0.0036,80001,138,177Jul 17 04:59 PM
Cantor Maria ESVP, Corporate Affairs and HRJun 02Sale6.903,71325,61184,461Jun 04 04:29 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerApr 02Sale8.222,40019,718230,642Apr 03 04:31 PM
Haluska FrankSVP, Clinical R&D, CMOApr 02Sale8.213,40027,916104,296Apr 03 04:32 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 02Sale8.216,50053,337403,028Apr 03 04:27 PM
Cantor Maria ESVP, Corporate Affairs and HRApr 02Sale8.214,25034,90788,174Apr 03 04:28 PM
Cantor Maria ESVP, Corporate Affairs and HRApr 01Option Exercise0.008,500092,424Apr 03 04:28 PM
CLACKSON TIMOTHY PPresident, R&D, CSOApr 01Option Exercise0.0013,0000409,528Apr 03 04:27 PM
Haluska FrankSVP, Clinical R&D, CMOApr 01Option Exercise0.008,5000107,696Apr 03 04:32 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerApr 01Option Exercise0.006,0000233,042Apr 03 04:31 PM
FITZGERALD EDWARD MExecutive VP, CFOApr 01Option Exercise0.0013,0000275,166Apr 03 04:29 PM
BERGER HARVEY J M DChairman & CEOApr 01Option Exercise0.0041,66701,142,908Apr 03 04:28 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerMar 21Sale7.891,60012,630227,042Mar 21 05:28 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 21Sale7.893,66728,93082,379Mar 21 05:30 PM
Haluska FrankSVP, Clinical R&D, CMOMar 21Sale7.892,40018,94199,196Mar 21 05:28 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 21Sale7.892,40018,936144,463Mar 21 05:21 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 21Sale7.896,66752,583394,377Mar 21 05:20 PM
BERGER HARVEY J M DChairman & CEOMar 20Option Exercise0.0034,00001,109,048Mar 21 04:09 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 20Option Exercise0.008,3330264,273Mar 21 04:10 PM
Duvall Martin JEVP, CCOMar 20Option Exercise0.001,666030,869Mar 21 04:11 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 20Option Exercise0.0013,3330401,044Mar 21 05:20 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 20Option Exercise0.006,0000146,863Mar 21 05:21 PM
Haluska FrankSVP, Clinical R&D, CMOMar 20Option Exercise0.006,0000101,596Mar 21 05:28 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 20Option Exercise0.007,333086,046Mar 21 05:30 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerMar 20Option Exercise0.004,0000228,642Mar 21 05:28 PM
BERSTEIN DAVID LSVP, GC and Chief IP OfficerMar 19Option Exercise0.004,7500226,148Mar 21 05:28 PM
Cantor Maria ESVP, Corporate Affairs and HRMar 19Option Exercise0.006,500080,774Mar 21 05:30 PM
Haluska FrankSVP, Clinical R&D, CMOMar 19Option Exercise0.006,500097,657Mar 21 05:28 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityMar 19Option Exercise0.008,0000143,399Mar 21 05:21 PM
CLACKSON TIMOTHY PPresident, R&D, CSOMar 19Option Exercise0.0010,8340391,153Mar 21 05:20 PM
Duvall Martin JEVP, CCOMar 19Option Exercise0.008,000031,821Mar 21 04:11 PM
FITZGERALD EDWARD MExecutive VP, CFOMar 19Option Exercise0.0010,8340259,375Mar 21 04:10 PM
BERGER HARVEY J M DChairman & CEOMar 19Option Exercise0.0036,00001,086,759Mar 21 04:09 PM
CLACKSON TIMOTHY PPresident, R&D, CSODec 19Sale5.149,75050,115380,319Dec 20 04:39 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerDec 19Sale5.144,50023,130221,398Dec 20 04:31 PM
Haluska FrankSVP, Clinical R&D, CMODec 19Sale5.145,10026,21491,157Dec 20 04:33 PM
Cantor Maria ESVP, Corporate AffairsDec 19Sale5.146,37532,76874,274Dec 20 04:35 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityDec 19Sale5.153,60018,528135,399Dec 20 04:38 PM
Bollag Daniel MSr. VP, Reg. Affairs & QualityDec 18Option Exercise0.009,0000138,999Dec 20 04:38 PM
FITZGERALD EDWARD MExecutive VP, CFODec 18Option Exercise0.0019,5000247,984Dec 20 04:37 PM
Cantor Maria ESVP, Corporate AffairsDec 18Option Exercise0.0012,750080,649Dec 20 04:35 PM
Haluska FrankSVP, Clinical R&D, CMODec 18Option Exercise0.0012,750096,257Dec 20 04:33 PM
BERGER HARVEY J M DChairman & CEODec 18Option Exercise0.0062,50001,080,259Dec 20 04:33 PM
BERSTEIN DAVID LSenior VP, Chief IP OfficerDec 18Option Exercise0.009,0000225,898Dec 20 04:31 PM
CLACKSON TIMOTHY PPresident, R&D, CSODec 18Option Exercise0.0019,5000390,069Dec 20 04:39 PM
DODION PIERRE FSVP, Corp. Dev. & OperationsNov 22Option Exercise0.0035,2500102,532Nov 22 04:36 PM